Hospital or health organisation · founded 1981
Moffitt Cancer Center
Tampa, United States · moffitt.org
- Citations, last 5 years
- 134.7k
- Works, last 5 years
- 13.7k
- h-index
- 815
- Scientists listed
- 0
- Grants since 2016
- 1 073
Grants received
2022–2024 · research · R21
Molecular Drivers of Lung Cancer in Hispanics
William Douglas Cress · Moffitt Cancer Center · funded by National Institutes of Health
2022–2027 · research · R01
Novel Therapy to Inhibit IPMN Progression
Surinder K. Batra · Moffitt Cancer Center · funded by National Institutes of Health
2022–2027 · research · R01
Defining and targeting epigenetic plasticity-driven drug resistance and immune escape in melanoma
Jonathan D. Licht · Moffitt Cancer Center · funded by National Institutes of Health
2022–2025 · award
Tumor-stroma metabolic crosstalk in melanoma brain metastases
Inna Smalley · Moffitt Cancer Center · funded by Melanoma Research Alliance
2022–2023 · research · R21
Defining and targeting the epigenetic programs involved in melanoma development
Keiran Smalley · Moffitt Cancer Center · funded by National Institutes of Health
2022–2027 · research · R37
Disrupting the Prostate Tumor Microenvironment in African American Men to Promote Response to Immuno-Modulatory Therapy
Kosj Yamoah · Moffitt Cancer Center · funded by National Institutes of Health
2022–2025 · award
Elucidating the oncogenic role of sMAF proteins in melanoma
Florian Karreth · Moffitt Cancer Center · funded by American Cancer Society
2022–2024 · award
Institutional Research Grant - Moffitt Cancer Center
Srikumar Chellappan · Moffitt Cancer Center · funded by American Cancer Society
2022–2027 · research · R01
Role of ULK3 in Sensitive and Refractory Multiple Myeloma
Conor C Lynch · Moffitt Cancer Center · funded by National Institutes of Health
2022–2024 · research · R21
Defining and targeting the immune-suppressive metabolic microenvironment of leptomeningeal melanoma metastases
Inna Smalley · Moffitt Cancer Center · funded by National Institutes of Health
2022–2023 · career development · K99
Targeting antioxidant vulnerabilities in KEAP1/NRF2 mutant NSCLC
Chang Jiang · Moffitt Cancer Center · funded by National Institutes of Health
2022–2027 · cooperative agreement · U01
Advancing Clinical Trials: Working through Outreach, Navigation and Digital Enabled Referral and Recruitment Strategies (ACT WONDERS)
Dana Elise Rollison · Moffitt Cancer Center · funded by National Institutes of Health
2022–2024 · research · R21
Exploiting Epigenetic Vulnerabilities In Glioblastoma Stem Cells Through Reprogramming
Arnold Etame · Moffitt Cancer Center · funded by National Institutes of Health
2022–2027 · research · R01
Mitochondrial stress promotes immunosuppressive potential of myeloid subsets in tumors
Paulo Cesar Rodriguez · Moffitt Cancer Center · funded by National Institutes of Health
2022–2025 · career development · K22
Tele-resistance training during chemotherapy for advanced upper gastrointestinal cancer
Nathan H Parker · Moffitt Cancer Center · funded by National Institutes of Health
2022–2026 · research · R00
Targeting antioxidant vulnerabilities in KEAP1/NRF2 mutant NSCLC
Chang Jiang · Moffitt Cancer Center · funded by National Institutes of Health
2022–2027 · research · R01
An Ionizing Radiation Acoustics Imaging (iRAI) Approach for guided Flash Radiotherapy
Thomas R. Bortfeld · Moffitt Cancer Center · funded by National Institutes of Health
2022–2024 · research · R03
The COACH Study: A Framework for individualized COaching in young Adult Cancer survivors to encourage Healthy behaviors
Sylvia Crowder · Moffitt Cancer Center · funded by National Institutes of Health
2022–2024 · research · R21
Developing GRB2-PROTACs for Treatment of Lung Cancer
Haitao Mark Ji · Moffitt Cancer Center · funded by National Institutes of Health
2022–2026 · research · R01
Augmented Reality as an Adjunct to Quitline Counseling for Smoking Cessation
Christine Vinci · Moffitt Cancer Center · funded by National Institutes of Health
2022–2024 · career development · K99
Cancer-related cognitive impairment: Real-time evaluation and assessment of long-term impact of treatment on young adult survivors (CRCI REALITY)
Danielle Tometich · Moffitt Cancer Center · funded by National Institutes of Health
2022–2027 · research · R01
Defining and targeting epigenetic plasticity-driven drug resistance and immune escape in melanoma
Jonathan D. Licht · Moffitt Cancer Center · funded by National Institutes of Health
2022–2024 · research · R03
The COACH Study: A Framework for individualized COaching in young Adult Cancer survivors to encourage Healthy behaviors
Sylvia Crowder · Moffitt Cancer Center · funded by National Institutes of Health
2022–2023 · grant · S10
Dual Source Ion Mobility-Mass Spectrometer
John M Koomen · Moffitt Cancer Center · funded by National Institutes of Health
2022–2027 · research · R01
Novel Therapy to Inhibit IPMN Progression
Surinder K. Batra · Moffitt Cancer Center · funded by National Institutes of Health
2022–2027 · research · R37
Characterizing cytotoxic therapy induced shifts in the cost-to-benefit ratio of high ploidy
Noemi Andor · Moffitt Cancer Center · funded by National Institutes of Health
2022–2024 · award
Novel mouse models of uveal melanoma
Florian Karreth · Moffitt Cancer Center · funded by Melanoma Research Alliance
2022–2025 · career development · K22
Tele-resistance training during chemotherapy for advanced upper gastrointestinal cancer
Nathan H Parker · Moffitt Cancer Center · funded by National Institutes of Health
2022–2027 · research · R01
An Ionizing Radiation Acoustics Imaging (iRAI) Approach for guided Flash Radiotherapy
Thomas R. Bortfeld · Moffitt Cancer Center · funded by National Institutes of Health
2022–2027 · research · R01
Oral HPV Research Among Latin Americans Living with HIV (ORAL - H² Study)
Anna R. Giuliano · Moffitt Cancer Center · funded by National Institutes of Health
2022–2024 · research · R21
Defining and targeting the epigenetic programs involved in melanoma development
Keiran Smalley · Moffitt Cancer Center · funded by National Institutes of Health
2022–2027 · research · R01
Novel Therapy to Inhibit IPMN Progression
Surinder K. Batra · Moffitt Cancer Center · funded by National Institutes of Health
2022–2027 · research · R37
Disrupting the Prostate Tumor Microenvironment in African American Men to Promote Response to Immuno-Modulatory Therapy
Kosj Yamoah · Moffitt Cancer Center · funded by National Institutes of Health
2022–2023 · career development · K99
Cancer-related cognitive impairment: Real-time evaluation and assessment of long-term impact of treatment on young adult survivors (CRCI REALITY)
Danielle Tometich · Moffitt Cancer Center · funded by National Institutes of Health
2022–2026 · research · R01
Role of CRTC1-MAML2 in Salivary Mucoepidermoid Carcinoma Pathobiology
Antonio Luigi Amelio · Moffitt Cancer Center · funded by National Institutes of Health
2022–2027 · research · R01
Mitochondrial stress promotes immunosuppressive potential of myeloid subsets in tumors
Paulo Cesar Rodriguez · Moffitt Cancer Center · funded by National Institutes of Health
2022–2025 · grant · Standard Grant
SCenE - Self-Assessment and Continual Learning on Edge Devices
Ghulam Rasool · Moffitt Cancer Center · funded by National Science Foundation
2022–2027 · research · R01
Role of ULK3 in Sensitive and Refractory Multiple Myeloma
Conor C Lynch · Moffitt Cancer Center · funded by National Institutes of Health
2022–2026 · career development · K22
Tele-resistance training during chemotherapy for advanced upper gastrointestinal cancer
Nathan H Parker · Moffitt Cancer Center · funded by National Institutes of Health
2022–2027 · research · R01
Oral HPV Research Among Latin Americans Living with HIV (ORAL - H² Study)
Anna R. Giuliano · Moffitt Cancer Center · funded by National Institutes of Health